Epirus, Polpharma partner on biosimilars in some markets
This article was originally published in Scrip
Executive Summary
US biosimilar developer Epirus Biopharmaceuticals entered into a profit-sharing agreement with Polish generic medicines specialist Polpharma Group for development and commercialization in certain EU markets as well as the Middle East, Turkey, Russia and the Commonwealth of Independent States (CIS).